No Data
No Data
Express News | Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $20 Price Target
Bio-Path Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 1011.11% Roth MKM $20 → $20 Reiterates Buy → Buy 04/18/2024 2122.22% Roth MKM → $40 Reiterates
Express News | Bio Path Holdings : Prexigebersen Phase 2 Clinical Trial Currently Paused for Interim Analysis, Amendment Preparation, FDA Review
Express News | Bio Path Holdings Inc: Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications
Express News | Bio-Path Holdings Provides Clinical Update and Expansion Plans
Express News | Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion by 2029 as Clinical Trials Increase